Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcia A Wheeler

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Urology|May 7, 2002
A comparison of multiple urine markers for interstitial cystitisDeborah R Erickson, Sharon X Xie, Veer P Bhavanandan, et al.
The Journal of Urology|January 16, 2007
Changes in urine markers and symptoms after bladder distention for interstitial cystitisDeborah R Erickson, Allen R Kunselman, Christina M Bentley, et al.
Molecular Cancer Therapeutics|November 14, 2013
Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancerDarryl T Martin, Jill M Steinbach, Jingchun Liu, et al.
The Journal of Urology|March 21, 2008
Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndromeDeborah R Erickson, John E Tomaszewski, Allen R Kunselman, et al.
The Journal of Urology|December 14, 2004
Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis?Deborah R Erickson, John E Tomaszewski, Allen R Kunselman, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 15, 2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancerDarryl T Martin, Christopher J Hoimes, Hristos Z Kaimakliotis, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patientsEdward Messing, Jason R Gee, Daniel R Saltzstein, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Urology|May 7, 2002
A comparison of multiple urine markers for interstitial cystitisDeborah R Erickson, Sharon X Xie, Veer P Bhavanandan, et al.
The Journal of Urology|January 16, 2007
Changes in urine markers and symptoms after bladder distention for interstitial cystitisDeborah R Erickson, Allen R Kunselman, Christina M Bentley, et al.
Molecular Cancer Therapeutics|November 14, 2013
Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancerDarryl T Martin, Jill M Steinbach, Jingchun Liu, et al.
The Journal of Urology|March 21, 2008
Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndromeDeborah R Erickson, John E Tomaszewski, Allen R Kunselman, et al.
The Journal of Urology|December 14, 2004
Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis?Deborah R Erickson, John E Tomaszewski, Allen R Kunselman, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 15, 2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancerDarryl T Martin, Christopher J Hoimes, Hristos Z Kaimakliotis, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 2, 2012
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patientsEdward Messing, Jason R Gee, Daniel R Saltzstein, et al.
Pageof 2